Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Biochem Biophys Res Commun ; 545: 145-149, 2021 03 19.
Article in English | MEDLINE | ID: mdl-33550095

ABSTRACT

In March 2013 it was reported by the World Health Organization (WHO) the first cases of human infections with avian influenza virus A (H7N9). From 2013 to December 2019, 1568 cases have been reported with 616 deaths. H7N9 infection has been associated with high morbidity and mortality rates, and vaccination is currently the most effective way to prevent infections and consequently flu-related severe illness. Developing and producing vaccines against pandemic influenza viruses is the main strategy for a response to a possible pandemic. This study aims to present the production of three industrial lots under current Good Manufacturing Practices (cGMP) of the active antigen used to produce the pandemic influenza vaccine candidate against A(H7N9). These batches were characterized and evaluated for quality standards and tested for immunogenicity in mice. The average yield was 173.50 ± 7.88 µg/mL of hemagglutinin and all the preparations met all the required specifications. The formulated H7N9 vaccine is poorly immunogenic and needs to be adjuvanted with an oil in water emulsion adjuvant (IB160) to achieve a best immune response, in a prime and in a boost scheme. These data are important for initial production planning and preparedness in the case of a H7N9 pandemic.


Subject(s)
Influenza A Virus, H7N9 Subtype/immunology , Influenza Vaccines/biosynthesis , Influenza, Human/prevention & control , Pandemics/prevention & control , Animals , Antigens, Viral/biosynthesis , Antigens, Viral/immunology , Drug Compounding/methods , Drug Compounding/statistics & numerical data , Drug Industry/standards , Female , Humans , Influenza Vaccines/immunology , Influenza Vaccines/isolation & purification , Influenza, Human/immunology , Influenza, Human/virology , Mice , Mice, Inbred BALB C , Vaccines, Inactivated/biosynthesis , Vaccines, Inactivated/immunology , Vaccines, Inactivated/isolation & purification
2.
J Ethnopharmacol ; 271: 113832, 2021 May 10.
Article in English | MEDLINE | ID: mdl-33460758

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: Baccharis trimera (Less.) DC known as "carqueja" in Brazil has been acknowledged as a medicinal plant in folk medicine for the treatment of stomach aches and gastrointestinal disorders. AIM OF THE STUDY: The present study aimed to evaluate the gastroprotective and healing effects of essential oil from B. trimera (EOBT) against gastric ulcer lesions caused by absolute ethanol and acetic acid, respectively, and to identify the mechanism of action of this essential oil in male Wistar rats. MATERIALS AND METHODS: The plant material used to obtain EOBT was collected in the southern region of Brazil and was analyzed by chromatography-mass spectrometry (GCMS) demonstrate its characteristic chemical composition, with carquejyl acetate as its main component. Different doses of EOBT (50, 100, and 200 mg/kg) were administered orally in male Wistar rats as an acute treatment against absolute ethanol-induced gastric lesions. The gastric healing effect of EOBT (100 mg/kg) was evaluated once a day after 7, 10, and 14 days of treatment. After treatment, the stomachs of rats from all groups were collected to measure the lesion area (mm2), the activity of myeloperoxidase (MPO), and the relative expression of caspases -3, -8, -9, cyclooxygenase-1 (COX-1), cyclooxygenase-2 (COX-2), vascular endothelial growth factor (VEGF), and epidermal growth factor (EGF). The zymography method was used to elucidate the activity of matrix metalloproteinase-2 (MMP-2) and -9 (MMP-9) in the healing action of EOBT. We also analyzed toxicological parameters (body weight evolution and biochemical parameters) that could result after treatment with this essential oil for 14 days. RESULTS: Pretreatment with EOBT (100 and 200 mg/kg) significantly decreased the severity of gastric damage induced by absolute ethanol and decreased MPO activity in gastric tissue. After 10 and 14 days of treatment with EOBT (100 mg/kg) once a day, the lesion area was significantly reduced by 61% and 65.5%, respectively, compared to the negative control group. The gastric healing effect of EOBT was followed by a decrease in the expression of COX-1 compared to that in the negative control group. Notably, treatment with EOBT for 14 days increased the expression of VEGF compared to that using an anti-ulcer drug (lansoprazole). Additionally, analyses of MMP-2 and MMP-9 activities in the gastric mucosa confirmed the accelerated gastric healing effect of EOBT, with a significant decrease in the activity of pro-MMP-2. No sign of toxicity was observed after treatment with EOBT for 14 consecutive days. CONCLUSION: These findings indicated that EOBT was effective in preventing and accelerating ulcer healing by decreasing MPO activity, increasing VEGF expression, and decreasing MMP-2 activity. These actions collectively contribute to the rapid recovery of gastric mucosa following treatment with EOBT, without any observed toxicity.


Subject(s)
Anti-Ulcer Agents/pharmacology , Baccharis/chemistry , Matrix Metalloproteinase 2/metabolism , Oils, Volatile/pharmacology , Stomach Ulcer/drug therapy , Vascular Endothelial Growth Factor A/metabolism , Acetic Acid/toxicity , Animals , Anti-Ulcer Agents/therapeutic use , Anti-Ulcer Agents/toxicity , Brazil , Caspases/metabolism , Cyclooxygenase 1/metabolism , Cyclooxygenase 2/metabolism , Disease Models, Animal , Ethanol/toxicity , Gastric Mucosa/drug effects , Lansoprazole/pharmacology , Lansoprazole/therapeutic use , Male , Matrix Metalloproteinase 9/metabolism , Medicine, Traditional , Membrane Proteins/metabolism , Oils, Volatile/therapeutic use , Oils, Volatile/toxicity , Organ Size/drug effects , Rats, Wistar , Stomach Ulcer/chemically induced , Stomach Ulcer/metabolism , Stomach Ulcer/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...